immuno - oncology

Search documents
Xilio Therapeutics Announces Closing of $50.0 Million Public Offering
Globenewswire· 2025-06-05 22:38
Core Viewpoint - Xilio Therapeutics, Inc. has successfully closed a public offering of pre-funded warrants and common stock warrants, raising approximately $50 million, with potential total gross proceeds of up to $150 million by the end of 2026 if all warrants are exercised for cash [1][5]. Group 1: Offering Details - The offering included pre-funded warrants to purchase 66,676,000 shares of common stock, along with Series A, B, and C warrants, all sold together at a combined public offering price of $0.7499 [2][4]. - The Series B warrants are exercisable at $0.75 per share between November 1, 2025, and December 2, 2025, potentially generating an additional $50 million if fully exercised [4]. - The Series C warrants are also exercisable at $0.75 per share between June 1, 2026, and December 2, 2026, with the same potential additional proceeds of $50 million if fully exercised [4]. Group 2: Use of Proceeds - The net proceeds from the offering will be utilized to advance the development of Xilio's product candidates and for working capital and general corporate purposes [5]. Group 3: Company Overview - Xilio Therapeutics is a clinical-stage biotechnology company focused on developing tumor-activated immuno-oncology therapies aimed at improving cancer treatment outcomes while minimizing systemic side effects [8].
Xilio Therapeutics Announces Pricing of $50.0 Million Public Offering
Globenewswire· 2025-06-02 12:46
Core Viewpoint - Xilio Therapeutics, Inc. has announced a public offering of pre-funded warrants and various series of warrants to raise approximately $50 million, aimed at advancing its tumor-activated immuno-oncology therapies for cancer treatment [1][3][4]. Group 1: Offering Details - The public offering includes 66,676,000 pre-funded warrants and corresponding Series A, B, and C warrants, with a combined offering price of $0.7499 per unit [1]. - The offering is expected to close around June 5, 2025, pending customary closing conditions [1]. - The initial gross proceeds from the offering are projected to be approximately $50 million before deducting underwriting discounts and commissions [3]. Group 2: Warrant Specifications - Pre-funded warrants are immediately exercisable until fully exercised, while Series A warrants can be exercised starting December 1, 2025, with an exercise price of $0.75 per share [2]. - Series B warrants will be exercisable on or after November 1, 2025, and Series C warrants on or after June 1, 2026, both with an exercise price of $0.75 per share [2]. Group 3: Use of Proceeds - The net proceeds from the offering will be utilized to advance the development of product candidates and for working capital and general corporate purposes [4]. Group 4: Company Overview - Xilio Therapeutics is focused on developing tumor-activated immuno-oncology therapies designed to improve cancer treatment outcomes while minimizing systemic side effects [8].
Xilio Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire News Room· 2025-05-02 20:30
Company Overview - Xilio Therapeutics, Inc. is a clinical-stage biotechnology company focused on discovering and developing tumor-activated immuno-oncology therapies aimed at improving outcomes for cancer patients without the systemic side effects associated with current treatments [4]. Stock Option Grant - On May 1, 2025, the company granted a non-qualified stock option to purchase 5,000 shares of its common stock to a new employee under its 2022 Inducement Stock Incentive Plan [1]. - The exercise price for the stock options is set at $0.755 per share, which matches the closing price of the company's common stock on the grant date [2]. - The stock options have a ten-year term, with 25% of the shares vesting on the first anniversary of employment and the remaining 75% vesting in 36 equal monthly installments, contingent on continued service with the company [2][3]. Compliance and Inducement - The stock options are granted in accordance with Nasdaq Listing Rule 5635(c)(4) as an inducement material to the individual entering employment with the company [3].
Affimed Announces Receipt of NASDAQ Deficiency Notice Regarding Minimum Bid Price Requirement
Globenewswire· 2025-04-21 10:30
Core Points - Affimed N.V. has received a notice from Nasdaq indicating that its common shares have closed below the minimum bid price of $1.00 for the last 30 consecutive business days [1] - The company has until October 13, 2025, to regain compliance with the Minimum Bid Price Rule, with the possibility of transferring to the Nasdaq Capital Market for an additional 180 days if necessary [2] - The notice does not have an immediate effect on the listing or trading of the company's shares, and the company plans to monitor its bid price and explore options for compliance [3] Company Overview - Affimed N.V. is a clinical-stage immuno-oncology company focused on harnessing the innate immune system to combat cancer through its proprietary innate cell engagers (ICE) [4] - The company is headquartered in Mannheim, Germany, and is led by a team of experienced biotechnology and pharmaceutical professionals [4]